NCT07636252Recruiting
Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 4 Jun 2026
- Start date
- 14 Jun 2023
- Primary completion date
- 1 Dec 2028
- Lead sponsor
- Sheba Medical Center
- Diseases
- Lung cancer
- NCT number
- NCT07636252
What you commit to
- Study type: Observational
- Planned participants: 400
- From 14 Jun 2023 to the primary completion date, 1 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- negative cytology for malignancy in the last 6 months
Who the study is looking for
- Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing.
- Patient's written informed consent present.
- Ability to understand the nature of the trial and the trial related procedures and to comply with them.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheba medical center Coordinator of this site? Confirm its status | Ramat Gan | Israel | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.